StockMarketWire.com - AstraZeneca said results from a clinical trial of its type-2 diabetes drug to treat patients with heart failure met its primary objective after showing a reduction of cardiovascular death or the worsening of heart failure when added to standard of care, compared to a placebo.

The trial was conducted in patients with reduced ejection fraction on standard of care treatment, including those with and without type-2 diabetes.

'With the DAPA-HF trial, Farxiga becomes the first in its class to demonstrate efficacy and safety data for the treatment of patients with heart failure, with and without type-2 diabetes, on top of standard of care. Today, half of heart failure patients will die within five years of diagnosis and it remains one of the leading causes of hospitalisation. We look forward to discussing the results of DAPA-HF with health authorities as soon as possible,' said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D.



Story provided by StockMarketWire.com